Aptamers and use of the aptamers in the diagnosis and treatment of cancer

An aptamer, wherein the aptamer comprises a nucleotide sequence (SEQ ID NO:

• 1) according to general formula (1) as given as follows or a pharmaceutically acceptable salt thereof:
• 5′-GCTGTGTGACTCCTGCAA-N43-GCAGCTGTATCTTGTCTCC-3′ (1) (SEQ ID NO:
• 1),
• wherein:
• N43 is a nucleotide sequence selected from the group comprising:
• 5′-CCGGACTGCAGAGACCGTCTGTCGGTGAACACTATTAGACGCG-3′ (SEQ ID NO:
• 2),
• 5′-CGTTGTTTGTTCGCTCCGGGCTGTAGAGCCTCGAAGATGAGTT-3′ (SEQ ID NO:
• 3),
• 5′-CAGGCCGGAGGGACTGGGGAGGTGCGACGTTTACGTGTTCTCC-3′ (SEQ ID NO:
• 4),
• 5′-CCAGACCGTAGGGGCTGTCTGTAGAGGACGCTGACGCGCACGA-3′ (SEQ ID NO:
• 5),
• 5′-CCTGTTCGGGCGCTAGCCTGATAGAAGTGTGCGTTCAATGGTG-3′ (SEQ ID NO:
• 6),
• 5′-CAGGTTGGGCTGATGGTGGGCAGACCGTAGGGTCCGTAATCCG-3′ (SEQ ID NO:
• 7),
• 5′-GGCGGTACGCGTGTGGACAGAAGTGACCGCCAAATAGCGCCTG-3′ (SEQ ID NO:
• 8),
• 5′-GGGGTACACGCGCATGCTCATCTGGACCGGAGGGTTCCGGGGA-3′ (SEQ ID NO:
• 9),
• 5′-CAAAGGGTCGGCGGACTGTTGAGACCACCGGCAGCGGGGCATT-3′ (SEQ ID NO:
• 10),
• 5′-GGGTACGGCATTGATTTGCTGCCTTATTGGTGTTGGTGGGGGG-3′ (SEQ ID NO:
• 11),
• 5′-CATGCTTTATGTAACAGGCGGAGGCCGTCCGTGGTACAGGTTC-3′ (SEQ ID NO:
• 12) and
• 5′-GGAGGGGATCACACCGTATAGACTGCAGAGTTCTGTCGGTGTG-3′ (SEQ ID NO:
• 13),
• or wherein the aptamer comprises a nucleotide sequence selected from the group comprising SEQ ID NOs:
• 2 to 13 or a pharmaceutically acceptable salt thereof.